Published in Oncoimmunology on August 12, 2015
Targeting natural killer cells in cancer immunotherapy. Nat Immunol (2016) 1.06
Dendritic cell-derived exosomes for cancer therapy. J Clin Invest (2016) 0.91
Extracellular vesicles: masters of intercellular communication and potential clinical interventions. J Clin Invest (2016) 0.85
Extracellular Vesicles in Cancer: Cell-to-Cell Mediators of Metastasis. Cancer Cell (2016) 0.85
The Unique Molecular and Cellular Microenvironment of Ovarian Cancer. Front Oncol (2017) 0.81
Cancer-derived extracellular vesicles: friend and foe of tumour immunosurveillance. Philos Trans R Soc Lond B Biol Sci (2018) 0.80
Curcumin increases exosomal TCF21 thus suppressing exosome-induced lung cancer. Oncotarget (2016) 0.80
Modulation of Immune Responses by Exosomes Derived from Antigen-Presenting Cells. Clin Med Insights Pathol (2016) 0.80
RIG-I activation induces the release of extracellular vesicles with antitumor activity. Oncoimmunology (2016) 0.79
Extracellular Vesicles in Angiogenesis. Circ Res (2017) 0.78
Extracellular Vesicles in Chronic Obstructive Pulmonary Disease. Int J Mol Sci (2016) 0.77
CBP/p300 acetyltransferases regulate the expression of NKG2D ligands on tumor cells. Oncogene (2016) 0.77
Extracellular vesicles of ETV2 transfected fibroblasts stimulate endothelial cells and improve neovascularization in a murine model of hindlimb ischemia. Cytotechnology (2017) 0.76
Qualitative differences in T-cell activation by dendritic cell-derived extracellular vesicle subtypes. EMBO J (2017) 0.76
Exosomes in cancer theranostic: Diamonds in the rough. Cell Adh Migr (2017) 0.75
Exosome-Based Cancer Therapy: Implication for Targeting Cancer Stem Cells. Front Pharmacol (2017) 0.75
Exosomes in tumor microenvironment: novel transporters and biomarkers. J Transl Med (2016) 0.75
Dendritic cell-derived exosomes for cancer immunotherapy: hope and challenges. Ann Transl Med (2017) 0.75
Donor-derived exosomes: the trick behind the semidirect pathway of allorecognition. Curr Opin Organ Transplant (2016) 0.75
The role of pancreatic cancer-derived exosomes in cancer progress and their potential application as biomarkers. Clin Transl Oncol (2017) 0.75
Harnessing the immune response to target tumors. F1000Res (2017) 0.75
Trial watch: Dendritic cell-based anticancer immunotherapy. Oncoimmunology (2017) 0.75
Extracellular vesicles as emerging targets in cancer: Recent development from bench to bedside. Biochim Biophys Acta (2017) 0.75
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol (2008) 7.35
Oncology meets immunology: the cancer-immunity cycle. Immunity (2013) 5.60
Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol (2012) 4.44
Regulation of MHC class II expression by interferon-gamma mediated by the transactivator gene CIITA. Science (1994) 3.71
Regulation of immune responses by extracellular vesicles. Nat Rev Immunol (2014) 3.24
Alternatively spliced NKp30 isoforms affect the prognosis of gastrointestinal stromal tumors. Nat Med (2011) 3.03
Production and characterization of clinical grade exosomes derived from dendritic cells. J Immunol Methods (2002) 2.77
Heat shock protein 70 surface-positive tumor exosomes stimulate migratory and cytolytic activity of natural killer cells. Cancer Res (2005) 2.72
ICAM-1 on exosomes from mature dendritic cells is critical for efficient naive T-cell priming. Blood (2005) 2.34
Vaccination of metastatic melanoma patients with autologous dendritic cell (DC) derived-exosomes: results of thefirst phase I clinical trial. J Transl Med (2005) 2.33
A phase I study of dexosome immunotherapy in patients with advanced non-small cell lung cancer. J Transl Med (2005) 2.26
Human leukocyte antigen-B-associated transcript 3 is released from tumor cells and engages the NKp30 receptor on natural killer cells. Immunity (2007) 2.20
Profound coordinated alterations of intratumoral NK cell phenotype and function in lung carcinoma. Cancer Res (2011) 1.91
Frequent and specific immunity to the embryonal stem cell-associated antigen SOX2 in patients with monoclonal gammopathy. J Exp Med (2007) 1.73
Dendritic cell-derived exosomes promote natural killer cell activation and proliferation: a role for NKG2D ligands and IL-15Ralpha. PLoS One (2009) 1.70
Dendritic cells release HLA-B-associated transcript-3 positive exosomes to regulate natural killer function. PLoS One (2008) 1.63
Mature dendritic cells secrete exosomes with strong ability to induce antigen-specific effector immune responses. Blood Cells Mol Dis (2005) 1.54
Reversible inhibition of Hsp70 chaperone function by Scythe and Reaper. EMBO J (2001) 1.50
Making friends in out-of-the-way places: how cells of the immune system get together and how they conduct their business as revealed by intravital imaging. Immunol Rev (2008) 1.47
Dendritic cell-derived exosomes for cancer immunotherapy: what's next? Cancer Res (2010) 1.43
Harnessing the power of the immune system to target cancer. Annu Rev Med (2012) 1.33
Interaction of heat shock protein 70 peptide with NK cells involves the NK receptor CD94. Biol Chem (2003) 1.28
The prognostic value of intraepithelial and stromal innate immune system cells in non-small cell lung carcinoma. Histopathology (2009) 1.28
Soluble ligands for NK cell receptors promote evasion of chronic lymphocytic leukemia cells from NK cell anti-tumor activity. Blood (2013) 1.22
Induction of B7-H6, a ligand for the natural killer cell-activating receptor NKp30, in inflammatory conditions. Blood (2013) 1.19
The prognostic value of natural killer cell infiltration in resected pulmonary adenocarcinoma. J Thorac Cardiovasc Surg (2001) 1.18
Rescue of impaired NK cell activity in hodgkin lymphoma with bispecific antibodies in vitro and in patients. Mol Ther (2013) 1.16
MHC class I-mediated exogenous antigen presentation by exosomes secreted from immature and mature bone marrow derived dendritic cells. Immunol Lett (2003) 1.14
Regulation of class II MHC expression in APCs: roles of types I, III, and IV class II transactivator. J Immunol (2002) 1.14
Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients. Sci Transl Med (2015) 1.09
Heat shock protein 70-reactivity is associated with increased cell surface density of CD94/CD56 on primary natural killer cells. Cell Stress Chaperones (2003) 1.07
Dendritic cell-derived exosomes as immunotherapies in the fight against cancer. J Immunol (2014) 1.05
Updated technology to produce highly immunogenic dendritic cell-derived exosomes of clinical grade: a critical role of interferon-γ. J Immunother (2011) 1.03
SOX2-specific adaptive immunity and response to immunotherapy in non-small cell lung cancer. Oncoimmunology (2013) 1.02
Chaperon and adjuvant activity of hsp70: different natural killer requirement for cross-priming of chaperoned and bystander antigens. Cancer Res (2005) 0.95
Sequential interplay between BAG6 and HSP70 upon heat shock. Cell Mol Life Sci (2009) 0.95
BAG-6, a jack of all trades in health and disease. Cell Mol Life Sci (2013) 0.89
γ-Interferon-regulated chaperone governs human lymphocyte antigen class II expression. FASEB J (2011) 0.86
Prognostic significance of spontaneous antibody responses against tumor-associated antigens in malignant melanoma patients. Int J Cancer (2014) 0.84
Maintenance strategies in stage IV non-small-cell lung cancer (NSCLC): in which patients, with which drugs? Ann Oncol (2013) 0.83